Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Personalized Neoantigen Peptide-Based Vaccine (Mayo Clinic)
- Development stage
- Unknown
- Lead developer
- Mayo Clinic
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
This personalized neoantigen peptide-based vaccine is an investigational immunotherapy developed by the Mayo Clinic for the treatment of advanced solid tumors, including triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC). The vaccine is custom-tailored for each patient by identifying unique tumor-specific mutations (neoantigens) through DNA and mRNA sequencing of the patient's tumor tissue using the REAL-neo bioinformatics pipeline. The active pharmaceutical ingredient consists of a pool of up to 20 synthetic long peptides, manufactured by Pepscan, which are designed to elicit a robust T-cell mediated immune response against the tumor cells. In clinical trials (e.g., PNeoVCA, NCT05269381), the vaccine is administered subcutaneously in combination with the adjuvant sargramostim (GM-CSF) and the checkpoint inhibitor pembrolizumab to maximize therapeutic efficacy.
- Other names
- Personalized Neoantigen Peptide-Based VaccineMayo Clinic Neoantigen VaccineNeoantigen Peptide Vaccine
02
Targets
MHC I (MHC class I})TLR3 (Toll-like receptor 3)
Beyond the preview
Go deeper on Personalized Neoantigen Peptide-Based Vaccine (Mayo Clinic).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Personalized Neoantigen Peptide-Based Vaccine (Mayo Clinic).